OTCMKTS:FSNUY Fresenius SE & Co. Earnings Date & Estimates $12.88 +0.11 (+0.86%) As of 10/23/2026 03:59 PM Eastern Fresenius SE & Co. is estimated to report earnings on Wednesday, November 4, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 4, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Fresenius SE & Co.Fresenius SE & Co. is expected to post earnings of $0.2156 per share on revenue of $6.51 billion. In the same quarter a year earlier Fresenius SE & Co. reported $0.23 per share on revenue of $6.29 billion. Fresenius SE & Co. last reported on August 5, 2026, posting $0.24 per share and missing the $0.25 consensus estimate. Fresenius SE & Co. has beaten the consensus EPS estimate in 3 of its last 5 quarters.Consensus EstimatesConsensus EPS$0.2156Expected Revenue$6.51 billionPrior-Year EPS$0.23Prior-Year Revenue$6.29 billionExpected EPS Growth-6.3%Expected Revenue Growth+3.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.24 (Missed by -$0.01)Last Quarter Revenue$6.91 billionEPS Beat Rate3 of last 5 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Fresenius SE & Co. Earnings FAQ When does Fresenius SE & Co. report earnings? Fresenius SE & Co. (OTCMKTS:FSNUY) is estimated to report earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Fresenius SE & Co.? Analysts expect Fresenius SE & Co. to post earnings of $0.2156 per share for the quarter. How much revenue is Fresenius SE & Co. expected to report? The consensus revenue estimate for Fresenius SE & Co. is $6.51 billion for the quarter. Fresenius SE & Co. Earnings HeadlinesFresenius : Q3 2026 Aide Memoire availableOctober 13, 2026 | marketscreener.comMFresenius Acquires Remaining 45% Stake In MAbxience For Up To EUR 750 MlnOctober 1, 2026 | rttnews.comFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider. | Weiss Ratings (Ad)Fresenius SE Takes Full Ownership of Biosimilars Platform mAbxienceOctober 1, 2026 | marketscreener.comMWaltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect PlatformSeptember 29, 2026 | prnewswire.comFresenius : expands European production capacity to enhance healthcare supply chain resilienceSeptember 25, 2026 | marketscreener.comMSee More Fresenius SE & Co. Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email. Email Address About Fresenius SE & Co.Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities. Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services. Fresenius also operates hospitals in Germany through its Helios division, which provides inpatient and outpatient medical care through a network of acute-care and rehabilitation facilities. Fresenius traces its origins to the Hirsch Pharmacy in Frankfurt, Germany, which was acquired by the Fresenius family in the 18th century. Over time, the business developed into an international health care company serving customers and patients across Europe, North America, Latin America, Asia and other global markets. Fresenius Medical Care, historically associated with the group’s dialysis business, has been managed as a separate company following Fresenius’ deconsolidation of its controlling interest. Fresenius SE & Co. KGaA is managed by Chief Executive Officer Michael Sen. The company is headquartered in Bad Homburg vor der Höhe, Germany.View Fresenius SE & Co. ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsPalantir's Next Big Test Isn't a Partnership—It's the NumbersKinder Morgan's $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings BeatCapital One Earnings: After a Double Beat the Rally Is OnTractor Supply's Q3 Beat Plants the Seeds for a Stock ReboundWD-40 Could Reward Patient Investors—Here's Why Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.